| 38.23 Data as of May 23 |  -0.03 / -0.08%Today’s Change | 28.12 Today|||52-Week Range 46.00 | +12.91% Year-to-Date |
| Neutral Rating Restated for Cepheid - Analyst Blog May 13 / Zacks.com |
| Previous close | 38.26 |
| Today’s open | 37.95 |
| Day’s range | 37.14 - 38.36 |
| Volume | 337,819 |
| Average volume (3 months) | 396,680 |
| Market cap | $2.6B |
| Dividend yield | -- |
| Earnings growth (last year) | -850.00% |
| Earnings growth (this year) | +103.87% |
| Earnings growth (next 5 years) | +15.00% |
| Revenue growth (last year) | +19.65% |
| P/E ratio | NM |
| Price/Sales | 6.71 |
| Price/Book | 10.29 |
| Today’s change | Today’s % change | |
|---|---|---|
| BIOBio-Rad Laboratories... | +0.18 | +0.16% |
| FEICFEI Co | +0.25 | +0.35% |
| BRKRBruker Corp | +0.06 | +0.35% |
| PKIPerkinElmer Inc | -0.06 | -0.19% |
| Next reporting date | July 25, 2013 |
| EPS forecast (this quarter) | -$0.04 |
| Annual revenue (last year) | $332.1M |
| Annual profit (last year) | -$20.0M |
| Net profit margin | -6.04% |
Sector Health Technology |
Industry Biotechnology |
Chairman & Chief Executive Officer John L. Bishop |
Chief Operating Officer & Executive Vice President Humberto Reyes |
Corporate headquarters Sunnyvale, California |
.
